DUSA Pharmaceuticals, Inc. to Present at the Roth Capital Partners 16th Annual Growth Stock Conference.Business Editors Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, 16th Annual Growth Stock Conference WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 16, 2004 DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area Pharmaceuticals, Inc. (Nasdaq:DUSA) announced today that Dr. Geoff Shulman, the Company's President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will be presenting on Thursday, February 19, 2004, at 8:00 a.m. (Pacific Time) at the Roth Capital Partners 16th Annual Growth Stock Conference taking place at the St. Regis Monarch Beach Resort and Spa in Dana Point, Calif. Dr. Shulman will provide an overview of the Company and its products, the Levulan(R) Kerastick(R) and the BLU-U(R) brand light source. The fundamentals of the technology platform will be reviewed and a summary of current and potential markets for the products will be highlighted. About DUSA Pharmaceuticals DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of Levulan Photodynamic Therapy photodynamic therapy n. A type of phototherapy in which a nontoxic light-sensitive compound that has been injected into a patient is exposed selectively to light, whereupon it becomes toxic to targeted malignant and other diseased cells. (PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT ) and Photodetection (PD) for multiple medical conditions See carpal tunnel syndrome, computer vision syndrome, dry eyes and deep vein thrombosis. . PDT and PD utilize light-activated compounds to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. DUSA maintains offices in Wilmington; Valhalla, N.Y.; and Toronto, Ontario. DUSA's first products, the Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source were launched in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. in September 2000 for the treatment of actinic actinic /ac·tin·ic/ (ak-tin´ik) producing chemical action; said of rays of light beyond the violet end of the spectrum. ac·tin·ic adj. keratoses, or AKs (precancerous precancerous /pre·can·cer·ous/ (-kan´ser-us) pertaining to a pathologic process that tends to become malignant. pre·can·cer·ous adj. skin lesions Skin Lesions Definition A skin lesion is a superficial growth or patch of the skin that does not resemble the area surrounding it. Description Skin lesions can be grouped into two categories: primary and secondary. ), of the face or scalp. The Company also continues to develop its Levulan PDT pipeline in both dermatological and internal indications. The presentation will be available over the Web at the above stated date and time by clicking on the following link: http://www.vcall.com/CEPage.asp?ID+85809. Upon completion of the live presentation, the archived presentation will be available within two hours and archived for up to twelve months. The presentation can also be viewed on www.rothcp.com and www.vcallconferences.com. About the Roth Capital Partners 16th Annual Growth Stock Conference This annual event is the largest in the nation for emerging growth companies. It provides a concentrated forum where Institutional Investors can meet the executives of growth companies hand picked by Roth Capital's research team. The conference will highlight approximately 225 companies from industry groups, including Health Care, Consumer Products, Technology and Financial Services. This year, as a result of numerous client requests, Roth has extended the conference to three working days, including a Discovery Day, which will highlight companies "undiscovered" by Wall Street. For more information about the conference visit http://www.apgweb.com/roth/danapoint/. Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to a planned presentation by DUSA's President and CEO which will overview DUSA's products, review fundamentals of its platform and summarize current and potential markets; and the availability of the presentation on the Web. Such risks and uncertainties include, but are not limited to, commencement of the conference, ability of Dr. Shulman to be present at the conference, continued regulatory approval of DUSA's products, clinical trial results, the regulatory approval process, ability to fund continued research and development, maintenance of DUSA's patent portfolio, and other risks identified in DUSA's SEC filings from time to time. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion